A recent report suggests that there is a steady increase in costs of FDA approved anticancer drugs over time, regardless of competition or supplemental indications. READ MORE

From The Journal

Medicine changes rapidly, but you can always count on Journal of Clinical Pathways for the latest information on value-based care. READ MORE
JCP staff were on hand to cover the meeting and engage with stakeholders throughout the weekend. We encourage all who are able to attend next year’s CPC, which will be held October 26-28, 2018, in Boston, MA. READ MORE
Journal of Clinical Pathways spoke with Dr Miller about a recent blog post, and how he sees future payment models adapting to an influx of costly new therapies as they enter the marker. READ MORE
New drugs for orphan and rare diseases have the potential to positively impact the lives of patients where historically few or no treatments had been available to manage the disease. READ MORE